GSK 1247446A

Drug Profile

GSK 1247446A

Alternative Names: GSK1247446A

Latest Information Update: 20 Nov 2013

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza virus infections

Most Recent Events

  • 20 Nov 2013 No development reported - Phase-II for Influenza virus infections prevention (adults) in Spain (IM)
  • 20 Nov 2013 No development reported - Phase-II for Influenza virus infections prevention (adults) in Germany (IM)
  • 20 Nov 2013 No development reported - Phase-II for Influenza virus infections prevention (adults) in France (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top